European Journal of Pharmacology, 152 (1988) 377–380
Elsevier

AUTHOR INDEX

Abbott, F.V.
Peripheral and central antinociceptive actions of ethylketocyclazocine in the formalin test (152) 93
Abiko, Y., see Miura, I. (152) 281
Ammon, H.P.T., see Verspohl, E.J. (152) 121
Andersen, P.H.
Differential effects of EEDQ on the dopamine D-1 receptor in vivo and in vitro (152) 153
Arbilla, S., see Lista, A. (152) 195
Athias, P., see De la Chapelle-Groz, B. (152) 111

Baeyens, J.M., see Barrios, M. (152) 175
Barrios, M. and Baeyens, J.M.
Differential effects of calcium channel blockers and stimulants on morphine withdrawal in vitro (152) 175
Benveniste, J., see Korth, R. (152) 101
Bergstrom, D.A., see Carlson, J.H. (152) 289
Bianchi, B.R., see Vickroy, T.W. (152) 371
Bidault, J., see Korth, R. (152) 101
Blandford, D.E., see Smyth, D.D. (152) 157
Boix, F., see Teruel, A.F. (152) 1
Bradford, H.F., see Croucher, M.J. (152) 29
Burleigh, D.E.
Opioid and non-opioid actions of loperamide on cholinergic nerve function in human isolated colon (152) 39
Buss, W.C., Savage, D.D., Stepanek, J., Little, S.A. and McGuffee, L.J.
Effect of calcium channel antagonists on calcium uptake and release by isolated rat cardiac mitochondria (152) 247

Carlson, J.H., Bergstrom, D.A., Demo, S.D. and Walters, J.R.
Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation (152) 289
Carlsson, A., see Hjorth, S. (152) 207
Ciliax, B.J., see Olson, J.M.M. (152) 47
Clark, D., see Hjorth, S. (152) 207
Coldwell, M.C., see Wilson, C. (152) 331
Conlon, J.M., see Katsoulis, S. (152) 363
Conte, B., see Maggi, C.A. (152) 273
Cooper, S.M., see Wilson, C. (152) 331
Crocker, A.D., see Faunt, J.E. (152) 255
Croucher, M.J., Bradford, H.F., Sunter, D.C. and Watkins, J.C.
Inhibition of the development of electrical kindling of the prepyriform cortex by daily focal injections of excitatory amino acid antagonists (152) 29

Cushing, D.J., McConnaughey, M.M. and Mustafa, S.J.
Characterization of adenosine binding sites in bovine testicular tissue using 8-cyclopentyl-1,3-[^{3}H]dipropylxanthine (152) 353

D'Amato, M., De Beurme, F.A. and Lefebvre, R.A.
Comparison of the effect of vasoactive intestinal polypeptide and non-adrenergic non-cholinergic neurone stimulation in the cat gastric fundus (152) 71
Dane, G., see Swayne, G.T.G. (152) 311
De Belleroche, J., see Rattray, M. (152) 163
De Beurme, F.A., see D'Amato, M. (152) 71
De la Chapelle-Groz, B. and Athias, P.
Gentamicin causes the fast depression of action potential and contraction in cultured cardiocytes (152) 111
Demo, S.D., see Carlson, J.H. (152) 289
Diener, M., Knobloch, S.F. and Rummel, W.
Action of loperamide on neuronally mediated and Ca^{2+}- or cAMP-mediated secretion in rat colon (152) 217
Dirksen, R., see Van der Laan, J.W. (152) 197
Dolan, J., see Swayne, G.T.G. (152) 311
Dolin, S.J., Hunter, A.B., Halsey, M.J. and Little, H.J.
Anticonvulsant profile of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine (152) 19

Emson, P., see Markstein, R. (152) 147
Endoh, M., see Hiramoto, T. (152) 301
Escorihuela, R.M., see Teruel, A.F. (152) 1

Faunt, J.E. and Crocker, A.D.
Adrenocortical hormone status affects responses to dopamine receptor agonists (152) 255
Feifel, R., see Lambrecht, G. (152) 193
Forth, B., see Lambrecht, G. (152) 193
Fung, Y.K. and Lau, Y.-S.
Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats (152) 263
Furio, M., see Maggi, C.A. (152) 273

Garzón, J., see Sánchez-Blázquez, P. (152) 357
Giuliani, S., see Maggi, C.A. (152) 273
Godfrey, P.P., Grahame-Smith, D.G. and Gray, J.A.
$GABA_B$ receptor activation inhibits 5-hydroxytryptamine-stimulated inositol phospholipid turnover in mouse cerebral cortex (152) 185
Goto, K., see Tomobe, Y. (152) 373
Gragnani, L., see Maggi, C.A. (152) 273

0014-2999/88/$03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division)

Grahame-Smith, D.G., see Godfrey, P.P. (152) 185
Gray, J.A., see Godfrey, P.P. (152) 185
Greener, M., see Swayne, G.T.G. (152) 311

Halpern, W., see Tesfamariam, B. (152) 167
Halsey, M.J., see Dolin, S.J. (152) 19
Hamilton, C.A. and Reid, J.L.
α_1-Adrenoceptor desensitisation (152) 179
Hamilton, T.C., see Wilson, C. (152) 331
Hashizume, H., see Miura, I. (152) 281
Henricks, P.A.J., Van Esch, B., Van Oosterhout, A.J.M. and Nijkamp, F.P.
Specific and non-specific effects of β-adrenoceptor agonists on guinea pig alveolar macrophage function (152) 321
Hiramoto, T., Kushida, H. and Endoh, M.
Further characterization of the myocardial α-adrenoceptors mediating positive inotropic effects in the rabbit myocardium (152) 301
Hiraoka, C., see Nakata, Y. (152) 171
Hirose, K., see Hori, Y. (152) 235
Hjorth, S., Clark, D. and Carlsson, A.
Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation (152) 207
Hollox, K.J., see Leach, M.J. (152) 189
Hönack, D., see Löscher, W. (152) 9
Hori, Y., Jyoyama, H., Yamada, K., Takagi, M., Hirose, K. and Katori, M.
Time course analyses of kinins and other mediators in plasma exudation of rat kaolin-induced pleurisy (152) 235
Howlett, D.R., see Wilson, C. (152) 331
Hunter, A.B., see Dolin, S.J. (152) 19

Iguchi, S., see Terawaki, T. (152) 63
Iwasa, T., see Iwasa, Y. (152) 135
Iwasa, Y., Iwasa, T., Yoshimura, T., Matsui, K. and Onaya, T.
The mechanism for the inhibitory action of N-(3′,4′-dimethoxycinnamoyl)anthranilic acid (tranilast) on the release reaction in platelets (152) 135

Johnson, K.M., Sacaan, A.I. and Snell, L.D.
Equilibrium analysis of [^{3}H]TCP binding: effects of glycine, magnesium and N-methyl-D-aspartate agonists (152) 141
Jordan, C.C., see Rattray, M. (152) 163
Jyoyama, H., see Hori, Y. (152) 235

Kamei, H., see Nabeshima, T. (152) 129
Kameswaran, L., see Thirugnanasambantham, P. (152) 367
Kameyama, T., see Nabeshima, T. (152) 129
Katori, M., see Hori, Y. (152) 235
Katsoulis, S. and Conlon, J.M.
Effects of neurotensin-related peptides on the motility of the guinea pig oesophagus (152) 363
Kawasaki, A., see Terawaki, T. (152) 63
Kerwin, Jr., J.F., see Vickroy, T.W. (152) 371
Kimura, A., Sato, A., Suzuki, A. and Suzuki, H.
Inhibitory effects of a new, potent, centrally acting muscle relaxant, (4S,5R)-4-(2-methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3- oxazolidin-2-one (NC-1200) on micturition contractions of the bladder in rats (152) 55
Kimura, S., see Tomobe, Y. (152) 373
Kira, H., see Terawaki, T. (152) 63
Knobloch, S.F., see Diener, M. (152) 217
Kopecka, H., see Vickroy, T.W. (152) 371
Korth, R., Nunez, D., Bidault, J. and Benveniste, J.
Comparison of three paf-acether receptor antagonist ginkgolides (152) 101
Krishnamurthy, V., see Thirugnanasambantham, P. (152) 367
Kushida, H., see Hiramoto, T. (152) 301

Lambrecht, G., Feifel, R., Forth, B., Strohmann, C., Tacke, R. and Mutschler, E.
p-Fluoro-hexahydro-sila-difenidol: The first $M_{2\beta}$-selective muscarinic antagonist (152) 193
Langer, S.Z., see Lista, A. (152) 195
Lau, Y.-S., see Fung, Y.K. (152) 263
Laverty, R., see Logan, B.J. (152) 227
Leach, M.J., Hollox, K.J., O'Donnell, R.A. and Miller, A.A.
Hippocampal NMDA/phencyclidine receptor binding sites are reduced following forebrain ischaemia in the gerbil (152) 189
Lefebvre, R.A., see D'Amato, M. (152) 71
Lista, A., Arbilla, S. and Langer, S.Z.
The facilitation by diazepam of the electrically evoked release of [^{3}H]5-HT from rat cortical slices is antagonized by picrotoxin and Ro 5-4864 (152) 195
Little, H.J., see Dolin, S.J. (152) 19
Little, S.A., see Buss, W.C. (152) 247
Logan, B.J., Laverty, R., Sanderson, W.D. and Yee, Y.B.
Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity (152) 227
Löscher, W., Nolting, B. and Hönack, D.
Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital (152) 9

Maggi, C.A., Giuliani, S., Patacchini, R., Conte, B., Furio, M., Santicioli, P., Meli, P., Gragnani, L. and Meli, A.
The effect of SC-19220, a prostaglandin antagonist, on the micturition reflex in rats (152) 273
Maguire, J., see Swayne, G.T.G. (152) 311
Mancini, W.R., see Olson, J.M.M. (152) 47
Markstein, R. and Emson, P.
Effect of neurotensin and its fragments neurotensin-(1-6) and neurotensin-(8-13) on dopamine release from cat striatum (152) 147
Martin, P., see Massol, J. (152) 347
Masaki, T., see Tomobe, Y. (152) 373
Massol, J., Martin, P., Soubrié, P. and Puech, A.J.
Triiodothyroacetic acid (TRIAC) potentiation of antidepressant-induced reversal of learned helplessness in rats (152) 347
Masuda, Y., see Terawaki, T. (152) 63
Matsui, K., see Iwasa, Y. (152) 135

McCaslin, P.P. and Smith, T.G.
Quisqualate, high calcium concentration and zero-chloride prevent kainate-induced toxicity of cerebellar granule cells (152) 341
McConnaughey, M.M., see Cushing, D.J. (152) 353
McGuffee, L.J., see Buss, W.C. (152) 247
Meli, A., see Maggi, C.A. (152) 273
Meli, P., see Maggi, C.A. (152) 273
Miller, A.A., see Leach, M.J. (152) 189
Miura, I., Hashizume, H. and Abiko, Y.
Propranolol inhibits accumulation of non-esterified fatty acids in the ischemic dog heart (152) 281
Miyauchi, T., see Tomobe, Y. (152) 373
Mustafa, S.J., see Cushing, D.J. (152) 353
Mutschler, E., see Lambrecht, G. (152) 193
Mythirayee, C.I., see Thirugnanasambantham, P. (152) 367

Nabeshima, T., Kamei, H. and Kameyama, T.
Opioid κ receptors correlate with the development of conditioned suppression of motility in mice (152) 129
Nadzan, A.M., see Vickroy, T.W. (152) 371
Nakata, Y., Hiraoka, C. and Segawa, T.
Apparent molecular weight of the substance P binding site in rat brain (152) 171
Nijkamp, F.P., see Henricks, P.A.J. (152) 321
Nolting, B., see Löscher, W. (152) 9
Nunez, D., see Korth, R. (152) 101

O'Donnell, R.A., see Leach, M.J. (152) 189
Okegawa, T., see Terawaki, T. (152) 63
Olson, J.M.M., Ciliax, B.J., Mancini, W.R. and Young, A.B.
Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes (152) 47
Onaya, T., see Iwasa, Y. (152) 135
Owen, D.A.A., see Swayne, G.T.G. (152) 311

Patacchini, R., see Maggi, C.A. (152) 273
Puech, A.J., see Massol, J. (152) 347

Ramachandran, S., see Thirugnanasambantham, P. (152) 367
Ramaswamy, S., see Thirugnanasambantham, P. (152) 367
Rattray, M., Jordan, C.C. and De Belleroche, J.
The novel CCK antagonist L364,718 abolishes caerulein- but potentiates morphine-induced antinociception (152) 163
Raval, P., see Swayne, G.T.G. (152) 311
Reid, J.L., see Hamilton, C.A. (152) 179
Rummel, W., see Diener, M. (152) 217

Sacaan, A.I., see Johnson, K.M. (152) 141
Saito, A., see Tomobe, Y. (152) 373
Sánchez-Blázquez, P. and Garzón, J.
Pertussis toxin differentially reduces the efficacy of opioids to produce supraspinal analgesia in the mouse (152) 357
Sanderson, W.D., see Logan, B.J. (152) 227
Santicioli, P., see Maggi, C.A. (152) 273
Sato, A., see Kimura, A. (152) 55
Savage, D.D., see Buss, W.C. (152) 247
Segawa, T., see Nakata, Y. (152) 171
Smith, T.G., see McCaslin, P.P. (152) 341
Smyth, D.D., Blandford, D.E. and Thom, S.L.
Disparate effects of neuropeptide Y and clonidine on the excretion of sodium and water in the rat (152) 157
Snell, L.D., see Johnson, K.M. (152) 141
Soubrié, P., see Massol, J. (152) 347
Stepanek, J., see Buss, W.C. (152) 247
Strickland, J.A. and Wooles, W.R.
Effect of acute and chronic ethanol on the agonist responses of vascular smooth muscle (152) 83
Strohmann, C., see Lambrecht, G. (152) 193
Sunter, D.C., see Croucher, M.J. (152) 29
Suzuki, A., see Kimura, A. (152) 55
Suzuki, H., see Kimura, A. (152) 55
Swayne, G.T.G., Maguire, J., Dolan, J., Raval, P., Dane, G., Greener, M. and Owen, D.A.A.
Evidence for homogeneity of thromboxane A_2 receptor using structurally different antagonists (152) 311

Tacke, R., see Lambrecht, G. (152) 193
Takagi, M., see Hori, Y. (152) 235
Takakuwa, T., see Terawaki, T. (152) 63
Terawaki, T., Takakuwa, T., Iguchi, S., Wakitani, K., Kira, H., Okegawa, T., Kawasaki, A. and Masuda, Y.
Effect of a prostacyclin analog OP-2507 on acute ischemic cerebral edema in cats (152) 63
Teruel, A.F., Boix, F., Escorihuela, R.M., Yáñez, P. and Tobeña, A.
Sodium valproate reduces immobility in the behavioral 'despair' test in rats (152) 1
Tesfamariam, B. and Halpern, W.
Asymmetry of responses to norepinephrine in perfused resistance arteries (152) 167
Thirugnanasambantham, P., Viswanathan, S., Ramaswamy, S., Krishnamurthy, V., Mythirayee, C.I., Ramachandran, S. and Kameswaran, L.
Involvement of calcium in flavonoid analgesia (152) 367
Thom, S.L., see Smyth, D.D. (152) 157
Tobeña, A., see Teruel, A.F. (152) 1
Tomobe, Y., Miyauchi, T., Saito, A., Yanagisawa, M., Kimura, S., Goto, K. and Masaki, T.
Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats (152) 373

Van der Laan, J.W. and Dirksen, R.
Dipropylacetate-induced shaking behaviour in the rat: a role of spinal α_2-adrenoceptors (152) 197
Van Esch, B., see Henricks, P.A.J. (152) 321
Van Oosterhout, A.J.M., see Henricks, P.A.J. (152) 321
Verspohl, E.J., Wunderle, G. and Ammon, H.P.T.
Proglumide antagonizes cholecystokinin effects on plasma glucose and insulin in rats in vivo (152) 121
Vickroy, T.W., Bianchi, B.R., Kerwin, Jr., J.F., Kopecka, H. and Nadzan, A.M.
Evidence that type A CCK receptors facilitate dopamine efflux in rat brain (152) 371
Viswanathan, S., see Thirugnanasambantham, P. (152) 367

Wakitani, K., see Terawaki, T. (152) 63
Walters, J.R., see Carlson, J.H. (152) 289
Watkins, J.C., see Croucher, M.J. (152) 29
Wilson, C., Coldwell, M.C., Howlett, D.R., Cooper, S.M. and Hamilton, T.C.
Comparative effects of K^+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil (152) 331
Wooles, W.R., see Strickland, J.A. (152) 83
Wunderle, G., see Verspohl, E.J. (152) 121

Yamada, K., see Hori, Y. (152) 235
Yanagisawa, M., see Tomobe, Y. (152) 373
Yáñez, P., see Teruel, A.F. (152) 1
Yee, Y.B., see Logan, B.J. (152) 227
Yoshimura, T., see Iwasa, Y. (152) 135
Young, A.B., see Olson, J.M.M. (152) 47

European Journal of Pharmacology, 152 (1988) 381–388
Elsevier

KEYWORD INDEX

Adenosine
Adenosine receptors; Testis (bovine); Spermatocytes; (Radioligand assay) (Cushing, D.J. (152) 353)

Adenosine receptors
Adenosine; Testis (bovine); Spermatocytes; (Radioligand assay) (Cushing, D.J. (152) 353)

Adrenalectomy
Dopamine receptors; Corticosterone; Apomorphine; LY171555; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

β-Adrenoceptor agonists
Adrenoceptors; Alveolar macrophage; Phagocyte function; Hydrogen peroxide production; (Guinea pig) (Henricks, P.A.J. (152) 321)

Adrenoceptors
β-Adrenoceptor agonists; Alveolar macrophage; Phagocyte function; Hydrogen peroxide production; (Guinea pig) (Henricks, P.A.J. (152) 321)

α-Adrenoceptors
Quasi-morphine withdrawal; Shaking behaviour; Di-n-propylacetate (valproate, DPA); Idazoxan; Prazosin; p-Aminoclonidine; Spinal cord (Van der Laan, J.W. (152) 197)

Positive inotropic effect; [^{3}H]Prazosin binding; Papillary muscle; Phenylephrine; YM-12617; (Rabbit) (Hiramoto, T. (152) 301)

α_1-Adrenoceptors
Phenylephrine; (Desensitisation, Down regulation) (Hamilton, C.A. (152) 179)

α_2-Adrenoceptors
Diuretics; Natriuretics; G_i protein (inhibitory); Clearance (free water, osmolar, creatinine) (Smyth, D.D. (152) 157)

Alveolar macrophage
Adrenoceptors; β-Adrenoceptor agonists; Phagocyte function; Hydrogen peroxide production; (Guinea pig) (Henricks, P.A.J. (152) 321)

p-Aminoclonidine
Quasi-morphine withdrawal; Shaking behaviour; Di-n-propylacetate (valproate, DPA); Idazoxan; Prazosin; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

Aminoglycosidic antibiotics
Gentamicin; Excitation-contraction coupling; Ca^{2+} antagonism; (Electrophysiology) (De la Chapelle-Groz, B. (152) 111)

cAMP
cGMP; Cyclic nucleotide phosphodiesterase; Thrombin; Blood platelet; Tranilast (Iwasa, Y. (152) 135)

Analgesia
Flavonoids; Ca^{2+} (Thirugnanasambantham, P. (152) 367)

Angiotensin II
Phenylephrine; Ethanol; Hypertension (Strickland, J.A. (152) 83)

Antidepressants
Triidothyroacetic acid (TRIAC); Learned helplessness; (Rat) (Massol, J. (152) 347)

Antinociception
Nociception; Opioids; Formalin test; Ethylketocyclazocine; Morphine; (Peripheral effects) (Abbott, F.V. (152) 93)

Caerulein; Cholecystokinin; CCK antagonists; Morphine (Rattray, M. (152) 163)

Apomorphine
Dopamine receptors; Adrenalectomy; Corticosterone; LY171555; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Baclofen
GABA; Serotonin (5-HT); Inositol phosphate (Godfrey, P.P. (152) 185)

Basal ganglia
Dopamine; Dopamine receptor agonists; Dopamine D-1 receptors; Dopamine D-2 receptors; Globus pallidus (Carlson, J.H. (152) 289)

Bay k 8644
Diltiazem; Verapamil; Ca^{2+} channels; Ca^{2+} channel blockers; Morphine withdrawal (Barrios, M. (152) 175)

Benzodiazepines (peripheral)
PK 11195; Erythrocytes; (Plasma membrane) (Olson, J.M.M. (152) 47)

0014-2999/88/$03.50 © 1988 Elsevier Science Publishers B.V. (Biomedical Division)

Bladder
Muscle relaxant (centrally acting); Pelvic nerve; Hypogastric nerve; Micturition contraction; (Rat) (Kimura, A. (152) 55)

Blood platelet
cAMP; cGMP; Cyclic nucleotide phosphodiesterase; Thrombin; Tranilast (Iwasa, Y. (152) 135)

BN 52020
Platelet-activating factor (PAF-acether, PAF); PAF receptor antagonists; Ginkgolides; BN 52021; BN 52022; BN 52063 (Korth, R. (152) 101)

BN 52021
Platelet-activating factor (PAF-acether, PAF); PAF receptor antagonists; Ginkgolides; BN 52020; BN 52022; BN 52063 (Korth, R. (152) 101)

BN 52022
Platelet-activating factor (PAF-acether, PAF); PAF receptor antagonists; Ginkgolides; BN 52021; BN 52020; BN 52063 (Korth, R. (152) 101)

BN 52063
Platelet-activating factor (PAF-acether, PAF); PAF receptor antagonists; Ginkgolides; BN 52021; BN 52020; BN 52022 (Korth, R. (152) 101)

Ca^{2+}
Kainate; Quisqualate; Cl^-; Cerebellum; Granule cells; (Toxicity) (McCaslin, P.P. (152) 341)

Flavonoids; Analgesia (Thirugnanasambantham, P. (152) 367)

Ca^{2+} antagonism
Gentamicin; Aminoglycosidic antibiotics; Excitation-contraction coupling; (Electrophysiology) (De la Chapelle-Groz, B. (152) 111)

Ca^{2+} channel antagonists
Convulsions; Pentylenetetrazol; Strychnine; High pressure neurological syndrome; N-Methyl-d-aspartate (NMDA) (Dolin, S.J. (152) 19)

Ca^{2+} flux; Ca^{2+} release; Ca^{2+} uptake; Cardiac mitochondria (Buss, W.C. (152) 247)

Ca^{2+} channel blockers
Diltiazem; Verapamil; Bay k 8644; Ca^{2+} channels; Morphine withdrawal (Barrios, M. (152) 175)

Ca^{2+} channels
Diltiazem; Verapamil; Bay k 8644; Ca^{2+} channel blockers; Morphine withdrawal (Barrios, M. (152) 175)

Caerulein
Cholecystokinin; CCK antagonists; Morphine; Antinociception (Rattray, M. (152) 163)

Ca^{2+} flux
Ca^{2+} channel antagonists; Ca^{2+} release; Ca^{2+} uptake; Cardiac mitochondria (Buss, W.C. (152) 247)

Calmodulin
Intestinal secretion; Loperamide (Diener, M. (152) 217)

Camostate
Proglumide; Cholecystokinin (CCK) receptor antagonists; Insulin (plasma); Glucose (plasma) (Verspohl, E.J. (152) 121)

Cardiac mitochondria
Ca^{2+} channel antagonists; Ca^{2+} flux; Ca^{2+} release; Ca^{2+} uptake (Buss, W.C. (152) 247)

Ca^{2+} release
Ca^{2+} channel antagonists; Ca^{2+} flux; Ca^{2+} uptake; Cardiac mitochondria (Buss, W.C. (152) 247)

Catecholamines
Methylenedioxyamphetamines; 5-Hydroxytryptamine; (Neurotoxicity, Species and strain differences) (Logan, B.J. (152) 227)

Ca^{2+} uptake
Ca^{2+} channel antagonists; Ca^{2+} flux; Ca^{2+} release; Cardiac mitochondria (Buss, W.C. (152) 247)

CCK antagonists
Caerulein; Cholecystokinin; Morphine; Antinociception (Rattray, M. (152) 163)

Central nervous system (CNS)
Dopamine (DA); Dopamine autoreceptors; (−)-3-PPP; (Functional up-regulation, Intrinsic agonist efficacy) (Hjorth, S. (152) 207)

Cerebellum
Kainate; Quisqualate; Ca^{2+}; Cl^-; Granule cells; (Toxicity) (McCaslin, P.P. (152) 341)

Cerebral artery occlusion
OP-2507; Prostacyclin analog (stable); Cerebral edema (ischemic); (Specific gravity of cerebral cortex) (Terawaki, T. (152) 63)

Cerebral edema (ischemic)
OP-2507; Prostacyclin analog (stable); Cerebral artery occlusion; (Specific gravity of cerebral cortex) (Terawaki, T. (152) 63)

Cholecystokinin
Caerulein; CCK antagonists; Morphine; Antinociception (Rattray, M. (152) 163)

Cholecystokinin (CCK) receptor antagonists
Proglumide; Insulin (plasma); Glucose (plasma); Camostate (Verspohl, E.J. (152) 121)

Cholinergic nerves
Loperamide; Verapamil; Colon; (Human) (Burleigh, D.E. (152) 39)

Cl^-
Kainate; Quisqualate; Ca^{2+}; Cerebellum; Granule cells; (Toxicity) (McCaslin, P.P. (152) 341)

Clearance (free water, osmolar, creatinine)
Diuretics; Natriuretics; G_i protein (inhibitory); α_2-Adrenoceptors (Smyth, D.D. (152) 157)

Colon
Loperamide; Verapamil; Cholinergic nerves; (Human) (Burleigh, D.E. (152) 39)

Convulsions
Ca^{2+} channel antagonists; Pentylenetetrazol; Strychnine; High pressure neurological syndrome; N-Methyl-d-aspartate (NMDA) (Dolin, S.J. (152) 19)

Cortex
N-Methyl-D-aspartate; Phencyclidine (PCP) receptors; Magnesium; Glycine; Glutamate; (Rat) (Johnson, K.M. (152) 141)

Substance P receptors; (Cross-linking, Rat) (Nakata, Y. (152) 171)

Corticosterone
Dopamine receptors; Adrenalectomy; Apomorphine; LY171555; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Cromakalim
Pinacidil; Nicorandil; K^+ channel blockers; $^{86}Rb^+$ efflux; Vasorelaxation (Wilson, C. (152) 331)

Cyclic nucleotide phosphodiesterase
cAMP; cGMP; Thrombin; Blood platelet; Tranilast (Iwasa, Y. (152) 135)

Diazepam
NMDA antagonists; Epilepsy; Phenobarbital; Kindling (Löscher, W. (152) 9)

Diltiazem
Verapamil; Bay k 8644; Ca^{2+} channels; Ca^{2+} channel blockers; Morphine withdrawal (Barrios, M. (152) 175)

Di-n-propylacetate (valproate, DPA)
Quasi-morphine withdrawal; Shaking behaviour; Idazoxan; Prazosin; p-Aminoclonidine; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

Diuretics
Natriuretics; G_i protein (inhibitory); Clearance (free water, osmolar, creatinine); α_2-Adrenoceptors (Smyth, D.D. (152) 157)

Dopamine
Nicotine; Striatum; (Hyperactivity) (Fung, Y.K. (152) 263)

Dopamine receptor agonists; Dopamine D-1 receptors; Dopamine D-2 receptors; Globus pallidus; Basal ganglia (Carlson, J.H. (152) 289)

Dopamine autoreceptors
Neurotensin; Striatum; (Cat) (Markstein, R. (152) 147)

Central nervous system (CNS); Dopamine (DA); (−)-3-PPP; (Functional up-regulation, Intrinsic agonist efficacy) (Hjorth, S. (152) 207)

Dopamine (DA)
Central nervous system (CNS); Dopamine autoreceptors; (−)-3-PPP; (Functional up-regulation, Intrinsic agonist efficacy) (Hjorth, S. (152) 207)

Dopamine D-1 receptors
Dopamine; Dopamine receptor agonists; Dopamine D-2 receptors; Globus pallidus; Basal ganglia (Carlson, J.H. (152) 289)

Dopamine D-2 receptors
Dopamine; Dopamine receptor agonists; Dopamine D-1 receptors; Globus pallidus; Basal ganglia (Carlson, J.H. (152) 289)

Dopamine receptor agonists
Dopamine; Dopamine D-1 receptors; Dopamine D-2 receptors; Globus pallidus; Basal ganglia (Carlson, J.H. (152) 289)

Dopamine receptors
Adrenalectomy; Corticosterone; Apomorphine; LY171555; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]-Spiperone binding (Faunt, J.E. (152) 255)

EEDQ
[^{3}H]SCH 23390; (Binding, In vivo, In vitro, Rat) (Andersen, P.H. (152) 153)

Endothelium
Neuronal uptake; Norepinephrine; (Intraluminal delivery, Extraluminal delivery) (Tesfamariam, B. (152) 167)

Epilepsy
NMDA antagonists; Diazepam; Phenobarbital; Kindling (Löscher, W. (152) 9)

Prepyriform cortex (deep); Kindling; Excitatory amino acid antagonists (Croucher, M.J. (152) 29)

Erythrocytes
Benzodiazepines (peripheral); PK 11195; (Plasma membrane) (Olson, J.M.M. (152) 47)

Ethanol
Angiotensin II; Phenylephrine; Hypertension (Strickland, J.A. (152) 83)

Ethylketocyclazocine
Nociception; Antinociception; Opioids; Formalin test; Morphine; (Peripheral effects) (Abbott, F.V. (152) 93)

Excitation-contraction coupling
Gentamicin; Aminoglycosidic antibiotics; Ca^{2+} antagonism; (Electrophysiology) (De la Chapelle-Groz, B. (152) 111)

Excitatory amino acid antagonists
Prepyriform cortex (deep); Kindling; Epilepsy (Croucher, M.J. (152) 29)

Fatty acids
Propranolol; Myocardium (ischemic); (Dog) (Miura, I. (152) 281)

Flavonoids
Ca^{2+}; Analgesia (Thirugnanasambantham, P. (152) 367)

Forced swimming test
Valproate; GABA antagonists (Teruel, A.F. (152) 1)

Formalin test
Nociception; Antinociception; Opioids; Ethylketocyclazocine; Morphine; (Peripheral effects) (Abbott, F.V. (152) 93)

GABA
Baclofen; Serotonin (5-HT); Inositol phosphate (Godfrey, P.P. (152) 185)

GABA antagonists
Forced swimming test; Valproate (Teruel, A.F. (152) 1)

Gastric fundus
Vasoactive intestinal polypeptide (VIP): Non-adrenergic non-cholinergic (NANC) relaxation; (Cat) (D'Amato, M. (152) 71)

Gentamicin
Aminoglycosidic antibiotics; Excitation-contraction coupling; Ca^{2+} antagonism; (Electrophysiology) (De la Chapelle-Groz, B. (152) 111)

Ginkgolides
Platelet-activating factor (PAF-acether, PAF); PAF receptor antagonists; BN 52021; BN 52020; BN 52022; BN 52063 (Korth, R. (152) 101)

Globus pallidus
Dopamine; Dopamine receptor agonists; Dopamine D-1 receptors; Dopamine D-2 receptors; Basal ganglia (Carlson, J.H. (152) 289)

Glucose (plasma)
Proglumide; Cholecystokinin (CCK) receptor antagonists; Insulin (plasma); Camostate (Verspohl, E.J. (152) 121)

Glutamate
N-Methyl-D-aspartate; Phencyclidine (PCP) receptors; Cortex; Magnesium; Glycine; (Rat) (Johnson, K.M. (152) 141)

Glycine
N-Methyl-D-aspartate; Phencyclidine (PCP) receptors; Cortex; Magnesium; Glutamate; (Rat) (Johnson, K.M. (152) 141)

cGMP
cAMP; Cyclic nucleotide phosphodiesterase; Thrombin; Blood platelet; Tranilast (Iwasa, Y. (152) 135)

G_i protein (inhibitory)
Diuretics; Natriuretics; Clearance (free water, osmolar, creatinine); α_2-Adrenoceptors (Smyth, D.D. (152) 157)

Granule cells
Kainate; Quisqualate; Ca^{2+}; Cl^-; Cerebellum; (Toxicity) (McCaslin, P.P. (152) 341)

High pressure neurological syndrome
Convulsions; Ca^{2+} channel antagonists; Pentylenetetrazol; Strychnine; N-Methyl-d-aspartate (NMDA) (Dolin, S.J. (152) 19)

Histamine
Kaolin-induced pleurisy; Plasma exudation; Kallikrein-kinin system; Prostaglandins (Hori, Y. (152) 235)

Hydrogen peroxide production
Adrenoceptors; β-Adrenoceptor agonists; Alveolar macrophage; Phagocyte function; (Guinea pig) (Henricks, P.A.J. (152) 321)

5-Hydroxytryptamine
Methylenedioxyamphetamines; Catecholamines; (Neurotoxicity, Species and strain differences) (Logan, B.J. (152) 227)

Hypertension
Angiotensin II; Phenylephrine; Ethanol (Strickland, J.A. (152) 83)

Hypogastric nerve
Muscle relaxant (centrally acting); Bladder; Pelvic nerve; Micturition contraction; (Rat) (Kimura, A. (152) 55)

Hypothermia
Dopamine receptors; Adrenalectomy; Corticosterone; Apomorphine; LY171555; Stereotypy; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Idazoxan
Quasi-morphine withdrawal; Shaking behaviour; Di-n-propylacetate (valproate, DPA); Prazosin; p-Aminoclonidine; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

Inositol phosphate
GABA; Baclofen; Serotonin (5-HT) (Godfrey, P.P. (152) 185)

Insulin (plasma)
Proglumide; Cholecystokinin (CCK) receptor antagonists; Glucose (plasma); Camostate (Verspohl, E.J. (152) 121)

Intestinal secretion
Loperamide; Calmodulin (Diener, M. (152) 217)

Ischaemia
N-(1-[2-Thienyl]cyclohexyl)piperidine (TCP); N-Methyl-D-aspartate (NMDA); (Gerbil) (Leach, M.J. (152) 189)

Kainate
Quisqualate; Ca^{2+}; Cl^-; Cerebellum; Granule cells; (Toxicity) (McCaslin, P.P. (152) 341)

Kallikrein-kinin system
Kaolin-induced pleurisy; Plasma exudation; Prostaglandins; Histamine (Hori, Y. (152) 235)

Kaolin-induced pleurisy
Plasma exudation; Kallikrein-kinin system; Prostaglandins; Histamine (Hori, Y. (152) 235)

K^+ channel blockers
Cromakalim; Pinacidil; Nicorandil; $^{86}Rb^+$ efflux; Vasorelaxation (Wilson, C. (152) 331)

Kindling
NMDA antagonists; Epilepsy; Diazepam; Phenobarbital (Löscher, W. (152) 9)

Prepyriform cortex (deep); Excitatory amino acid antagonists; Epilepsy (Croucher, M.J. (152) 29)

Kinetensin
Neurotensin; Neuromedin N; Xenopsin; Oesophagus; (Guinea-pig) (Katsoulis, S. (152) 363)

Learned helplessness
Triidothyroacetic acid (TRIAC); Antidepressants; (Rat) (Massol, J. (152) 347)

Loperamide
Verapamil; Colon; Cholinergic nerves; (Human) (Burleigh, D.E. (152) 39)

Intestinal secretion; Calmodulin (Diener, M. (152) 217)

LY171555
Dopamine receptors; Adrenalectomy; Corticosterone; Apomorphine; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Magnesium
N-Methyl-D-aspartate; Phencyclidine (PCP) receptors; Cortex; Glycine; Glutamate; (Rat) (Johnson, K.M. (152) 141)

N-Methyl-D-aspartate
Phencyclidine (PCP) receptors; Cortex; Magnesium; Glycine; Glutamate; (Rat) (Johnson, K.M. (152) 141)

N-Methyl-d-aspartate (NMDA)
Convulsions; Ca^{2+} channel antagonists; Pentylenetetrazol; Strychnine; High pressure neurological syndrome (Dolin, S.J. (152) 19)

N-Methyl-D-aspartate (NMDA)
Ischaemia; N-(1-[2-Thienyl]cyclohexyl)piperidine (TCP); (Gerbil) (Leach, M.J. (152) 189)

Methylenedioxyamphetamines
Catecholamines; 5-Hydroxytryptamine; (Neurotoxicity, Species and strain differences) (Logan, B.J. (152) 227)

Micturition contraction
Muscle relaxant (centrally acting); Bladder; Pelvic nerve; Hypogastric nerve; (Rat) (Kimura, A. (152) 55)

Micturition reflex
Urinary bladder; Prostanoids; SC-19220 (Maggi, C.A. (152) 273)

Morphine
Nociception; Antinociception; Opioids; Formalin test; Ethylketocyclazocine; (Peripheral effects) (Abbott, F.V. (152) 93)

Caerulein; Cholecystokinin; CCK antagonists; Antinociception (Rattray, M. (152) 163)

Morphine withdrawal
Diltiazem; Verapamil; Bay k 8644; Ca^{2+} channels; Ca^{2+} channel blockers (Barrios, M. (152) 175)

Muscle relaxant (centrally acting)
Bladder; Pelvic nerve; Hypogastric nerve; Micturition contraction; (Rat) (Kimura, A. (152) 55)

Myocardium (ischemic)
Propranolol; Fatty acids; (Dog) (Miura, I. (152) 281)

Natriuretics
Diuretics; G_i protein (inhibitory); Clearance (free water, osmolar, creatinine); α_2-Adrenoceptors (Smyth, D.D. (152) 157)

Neuromedin N
Neurotensin; Xenopsin; Kinetensin; Oesophagus; (Guinea-pig) (Katsoulis, S. (152) 363)

Neuronal uptake
Endothelium; Norepinephrine; (Intraluminal delivery, Extraluminal delivery) (Tesfamariam, B. (152) 167)

Neurotensin
Dopamine autoreceptors; Striatum; (Cat) (Markstein, R. (152) 147)

Neuromedin N; Xenopsin; Kinetensin; Oesophagus; (Guinea-pig) (Katsoulis, S. (152) 363)

Nicorandil
Cromakalim; Pinacidil; K^+ channel blockers; $^{86}Rb^+$ efflux; Vasorelaxation (Wilson, C. (152) 331)

Nicotine
Dopamine; Striatum; (Hyperactivity) (Fung, Y.K. (152) 263)

NMDA antagonists
Epilepsy; Diazepam; Phenobarbital; Kindling (Löscher, W. (152) 9)

Nociception
Antinociception; Opioids; Formalin test; Ethylketocyclazocine; Morphine; (Peripheral effects) (Abbott, F.V. (152) 93)

Non-adrenergic non-cholinergic (NANC) relaxation
Vasoactive intestinal polypeptide (VIP); Gastric fundus; (Cat) (D'Amato, M. (152) 71)

Norepinephrine
Endothelium; Neuronal uptake; (Intraluminal delivery, Extraluminal delivery) (Tesfamariam, B. (152) 167)

Oesophagus
Neurotensin; Neuromedin N; Xenopsin; Kinetensin; (Guinea-pig) (Katsoulis, S. (152) 363)

OP-2507
Prostacyclin analog (stable); Cerebral edema (ischemic); Cerebral artery occlusion; (Specific gravity of cerebral cortex) (Terawaki, T. (152) 63)

Opioid receptors
Pertussis toxin; Opioids; Supraspinal analgesia; (Agonist efficacy, Partial agonism) (Sánchez-Blázquez, P. (152) 357)

κ Opioid receptors
Opioid receptor types; Stress; (Conditioned suppression) (Nabeshima, T. (152) 129)

Opioid receptor types
κ Opioid receptors; Stress; (Conditioned suppression) (Nabeshima, T. (152) 129)

Opioids
Nociception; Antinociception; Formalin test; Ethylketocyclazocine; Morphine; (Peripheral effects) (Abbott, F.V. (152) 93)

Pertussis toxin; Supraspinal analgesia; Opioid receptors; (Agonist efficacy, Partial agonism) (Sánchez-Blázquez, P. (152) 357)

PAF receptor antagonists
Platelet-activating factor (PAF-acether, PAF); Ginkgolides; BN 52021; BN 52020; BN 52022; BN 52063 (Korth, R. (152) 101)

Papillary muscle
α-Adrenoceptors; Positive inotropic effect; [^{3}H]Prazosin binding; Phenylephrine; YM-12617; (Rabbit) (Hiramoto, T. (152) 301)

Pelvic nerve
Muscle relaxant (centrally acting); Bladder; Hypogastric nerve; Micturition contraction; (Rat) (Kimura, A. (152) 55)

Pentylenetetrazol
Convulsions; Ca^{2+} channel antagonists; Strychnine; High pressure neurological syndrome; N-Methyl-d-aspartate (NMDA) (Dolin, S.J. (152) 19)

Pertussis toxin
Opioids; Supraspinal analgesia; Opioid receptors; (Agonist efficacy, Partial agonism) (Sánchez-Blázquez, P. (152) 357)

Phagocyte function
Adrenoceptors; β-Adrenoceptor agonists; Alveolar macrophage; Hydrogen peroxide production; (Guinea pig) (Henricks, P.A.J. (152) 321)

Phencyclidine (PCP) receptors
N-Methyl-D-aspartate; Cortex; Magnesium; Glycine; Glutamate; (Rat) (Johnson, K.M. (152) 141)

Phenobarbital
NMDA antagonists; Epilepsy; Diazepam; Kindling (Löscher, W. (152) 9)

Phenylephrine
Angiotensin II; Ethanol; Hypertension (Strickland, J.A. (152) 83)

α_1-Adrenoceptors; (Desensitisation, Down regulation) (Hamilton, C.A. (152) 179)

α-Adrenoceptors; Positive inotropic effect; [^{3}H]Prazosin binding; Papillary muscle; YM-12617; (Rabbit) (Hiramoto, T. (152) 301)

Pinacidil
Cromakalim; Nicorandil; K^+ channel blockers; $^{86}Rb^+$ efflux; Vasorelaxation (Wilson, C. (152) 331)

PK 11195
Benzodiazepines (peripheral); Erythrocytes; (Plasma membrane) (Olson, J.M.M. (152) 47)

Plasma exudation
Kaolin-induced pleurisy; Kallikrein-kinin system; Prostaglandins; Histamine (Hori, Y. (152) 235)

Platelet-activating factor (PAF-acether, PAF)
PAF receptor antagonists; Ginkgolides; BN 52021; BN 52020; BN 52022; BN 52063 (Korth, R. (152) 101)

Positive inotropic effect
α-Adrenoceptors; [^{3}H]Prazosin binding; Papillary muscle; Phenylephrine; YM-12617; (Rabbit) (Hiramoto, T. (152) 301)

(−)-3-PPP
Central nervous system (CNS); Dopamine (DA); Dopamine autoreceptors; (Functional up-regulation, Intrinsic agonist efficacy) (Hjorth, S. (152) 207)

Prazosin
Quasi-morphine withdrawal; Shaking behaviour; Di-n-propylacetate (valproate, DPA); Idazoxan; p-Aminoclonidine; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

[^{3}H]Prazosin binding
α-Adrenoceptors; Positive inotropic effect; Papillary muscle; Phenylephrine; YM-12617; (Rabbit) (Hiramoto, T. (152) 301)

Prepyriform cortex (deep)
Kindling; Excitatory amino acid antagonists; Epilepsy (Croucher, M.J. (152) 29)

Proglumide
Cholecystokinin (CCK) receptor antagonists; Insulin (plasma); Glucose (plasma); Camostate (Verspohl, E.J. (152) 121)

Propranolol
Fatty acids; Myocardium (ischemic); (Dog) (Miura, I. (152) 281)

Prostacyclin analog (stable)
OP-2507; Cerebral edema (ischemic); Cerebral artery occlusion; (Specific gravity of cerebral cortex) (Terawaki, T. (152) 63)

Prostaglandins
Kaolin-induced pleurisy; Plasma exudation; Kallikrein-kinin system; Histamine (Hori, Y. (152) 235)

Prostanoids
Micturition reflex; Urinary bladder; SC-19220 (Maggi, C.A. (152) 273)

Quasi-morphine withdrawal
Shaking behaviour; Di-n-propylacetate (valproate, DPA); Idazoxan; Prazosin; p-Aminoclonidine; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

Quisqualate
Kainate; Ca^{2+}; Cl^-; Cerebellum; Granule cells; (Toxicity) (McCaslin, P.P. (152) 341)

$^{86}Rb^+$ efflux
Cromakalim; Pinacidil; Nicorandil; K^+ channel blockers; Vasorelaxation (Wilson, C. (152) 331)

SC-19220
Micturition reflex; Urinary bladder; Prostanoids (Maggi, C.A. (152) 273)

[^{3}H]SCH 23390
EEDQ; (Binding, In vivo, In vitro, Rat) (Andersen, P.H. (152) 153)

[^{3}H]SCH 23390 binding
Dopamine receptors; Adrenalectomy; Corticosterone; Apomorphine; LY171555; Stereotypy; Hypothermia; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Serotonin (5-HT)
GABA; Baclofen; Inositol phosphate (Godfrey, P.P. (152) 185)

Shaking behaviour
Quasi-morphine withdrawal; Di-n-propylacetate (valproate, DPA); Idazoxan; Prazosin; p-Aminoclonidine; α-Adrenoceptors; Spinal cord (Van der Laan, J.W. (152) 197)

Spermatocytes
Adenosine; Adenosine receptors; Testis (bovine); (Radioligand assay) (Cushing, D.J. (152) 353)

Spinal cord
Quasi-morphine withdrawal; Shaking behaviour; Di-n-propylacetate (valproate, DPA); Idazoxan; Prazosin; p-Aminoclonidine; α-Adrenoceptors (Van der Laan, J.W. (152) 197)

[^{3}H]Spiperone binding
Dopamine receptors; Adrenalectomy; Corticosterone; Apomorphine; LY171555; Stereotypy; Hypothermia; [^{3}H]SCH 23390 binding (Faunt, J.E. (152) 255)

Stereotypy
Dopamine receptors; Adrenalectomy; Corticosterone; Apomorphine; LY171555; Hypothermia; [^{3}H]SCH 23390 binding; [^{3}H]Spiperone binding (Faunt, J.E. (152) 255)

Stress
κ Opioid receptors; Opioid receptor types; (Conditioned suppression) (Nabeshima, T. (152) 129)

Striatum
Neurotensin; Dopamine autoreceptors; (Cat) (Markstein, R. (152) 147)

Nicotine; Dopamine; (Hyperactivity) (Fung, Y.K. (152) 263)

Strychnine
Convulsions; Ca^{2+} channel antagonists; Pentylenetetrazol; High pressure neurological syndrome; N-Methyl-d-aspartate (NMDA) (Dolin, S.J. (152) 19)

Substance P receptors
Cortex; (Cross-linking, Rat) (Nakata, Y. (152) 171)

Supraspinal analgesia
Pertussis toxin; Opioids; Opioid receptors; (Agonist efficacy, Partial agonism) (Sánchez-Blázquez, P. (152) 357)

Testis (bovine)
Adenosine; Adenosine receptors; Spermatocytes; (Radioligand assay) (Cushing, D.J. (152) 353)

N-(1-[2-Thienyl]cyclohexyl)piperidine (TCP)
Ischaemia; N-Methyl-D-aspartate (NMDA); (Gerbil) (Leach, M.J. (152) 189)

Thrombin
cAMP; cGMP; Cyclic nucleotide phosphodiesterase; Blood platelet; Tranilast (Iwasa, Y. (152) 135)

Thromboxane antagonists
Thromboxane receptors; (Receptor heterogeneity) (Swayne, G.T.G. (152) 311)

Thromboxane receptors
Thromboxane antagonists; (Receptor heterogeneity) (Swayne, G.T.G. (152) 311)

Tranilast
cAMP; cGMP; Cyclic nucleotide phosphodiesterase; Thrombin; Blood platelet (Iwasa, Y. (152) 135)

Triidothyroacetic acid (TRIAC)
Antidepressants; Learned helplessness; (Rat) (Massol, J. (152) 347)

Urinary bladder
Micturition reflex; Prostanoids; SC-19220 (Maggi, C.A. (152) 273)

Valproate
Forced swimming test; GABA antagonists (Teruel, A.F. (152) 1)

Vasoactive intestinal polypeptide (VIP)
Gastric fundus; Non-adrenergic non-cholinergic (NANC) relaxation; (Cat) (D'Amato, M. (152) 71)

Vasorelaxation
Cromakalim; Pinacidil; Nicorandil; K^+ channel blockers; $^{86}Rb^+$ efflux (Wilson, C. (152) 331)

Verapamil
Loperamide; Colon; Cholinergic nerves; (Human) (Burleigh, D.E. (152) 39)

Diltiazem; Bay k 8644; Ca^{2+} channels; Ca^{2+} channel blockers; Morphine withdrawal (Barrios, M. (152) 175)

Xenopsin
Neurotensin; Neuromedin N; Kinetensin; Oesophagus; (Guinea-pig) (Katsoulis, S. (152) 363)

YM-12617
α-Adrenoceptors; Positive inotropic effect; [^{3}H]Prazosin binding; Papillary muscle; Phenylephrine; (Rabbit) (Hiramoto, T. (152) 301)